London, Feb 16, 2026, 11:44 GMT — Regular session
- Fevertree Drinks slipped 0.4% in London, trailing gains seen across the broader market.
- The mixer maker said it snapped up 15,340 shares on Feb. 13, with plans to cancel the lot.
- Eyes are on the company’s preliminary results coming up March 24.
Fevertree Drinks FEVR.L slipped 0.4% to 965 pence as of 11:29 GMT, shaving roughly 3.8 pence off the share price for the day.
The company disclosed it picked up 15,340 shares on Feb. 13, paying between 953 and 969 pence apiece, with the volume-weighted average landing at 959.781 pence. It intends to cancel the repurchased stock.
Buybacks are modest in size, yet enough to keep the program in sight. With investors eyeing Fever-Tree’s U.S. reset as a “show me” situation, consistent capital returns could count as results approach.
The Feb. 13 repurchase falls under a buyback plan of up to 30 million pounds, managed by Investec. Fever-Tree has said the program may run until the end of 2026.
Fever-Tree, in its late-January trading update, projected that both full-year adjusted revenue and adjusted EBITDA would slightly top what the market had been expecting. The company said it was still on track for its 2026 goals, highlighting its advances with Molson Coors’ U.S. distribution network. Preliminary results are set for March 24.
Back then, Reuters noted Fever-Tree was guiding for 2025 adjusted revenue to hit 375.3 million pounds—coming in higher than the consensus figure of 372.4 million pounds put together by the company. Analysts were looking for adjusted core profit around 44.4 million pounds.
The clock just got tighter for the next few weeks. Investors are eyeing the guidance, gauging what the company reports on U.S. execution through the partnership, and tracking signs of demand beyond its main tonic lineup.
Still, buybacks don’t guarantee support. Should earnings come up short, or if marketing and distribution expenses take a bigger chunk than anticipated, shares may drop sharply despite ongoing repurchases.
